MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, TMCI had -$642K decrease in cash & cash equivalents over the period. -$29,487K in free cash flow.

Cash Flow Overview

Change in Cash
-$642K
Free Cash flow
-$29,487K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Sales and maturities of availabl...
    • Proceeds from interest bearing t...
    • Share-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Payments on interest bearing ter...
    • Purchases of available-for-sale ...
    • Others

Cash Flow
2025-12-31
Net loss
-59,002
Depreciation and amortization expense
10,623
Provision for allowance for credit losses
834
Share-based compensation expense
33,823
Non-cash lease expense
2,222
Amortization of debt issuance costs
292
Debt extinguishment loss
2,737
Amortization (accretion) of premium (discount) on marketable securities, net
123
Other, net
-1,208
Accounts receivable
2,090
Inventory
-3,224
Prepaid expenses and other assets
-166
Other non-current assets
503
Operating lease liabilities
-3,207
Accounts payable
-3,796
Accrued liabilities
-2,413
Other, net
-35
Net cash provided by (used in) operating activities
-15,970
Purchases of available-for-sale marketable securities
40,571
Sales and maturities of available-for-sale marketable securities
67,339
Purchases of property and equipment
13,517
Acquisition, net of cash acquired
0
Net cash provided by (used in) investing activities
13,251
Proceeds from interest bearing term debt
59,310
Proceeds from insurance premium financing
1,553
Debt issuance costs
1,199
Payments on interest bearing term and revolving debt
56,315
Payments on insurance premium financing
916
Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of 7.5 million
0
Proceeds from exercise of employee stock options
546
Taxes from withheld shares
902
Net cash provided by (used in) financing activities
2,077
Net increase (decrease) in cash and cash equivalents
-642
Cash and cash equivalents at beginning of period
11,350
Cash and cash equivalents at end of period
10,708
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Sales and maturitiesof...$67,339K Proceeds from interestbearing term debt$59,310K Proceeds from insurancepremium financing$1,553K Proceeds from exercise ofemployee stock options$546K Net cash provided by(used in) investing...$13,251K Net cash provided by(used in) financing...$2,077K Canceled cashflow$54,088K Canceled cashflow$59,332K Net increase(decrease) in cash and cash...-$642K Canceled cashflow$15,328K Share-based compensationexpense$33,823K Depreciation andamortization expense$10,623K Inventory-$3,224K Debt extinguishmentloss$2,737K Non-cash lease expense$2,222K Other, net-$1,208K Provision for allowancefor credit losses$834K Amortization of debt issuancecosts$292K Prepaid expenses andother assets-$166K Other, net-$35K Purchases ofavailable-for-sale marketable...$40,571K Purchases of property andequipment$13,517K Payments on interestbearing term and...$56,315K Debt issuance costs$1,199K Payments on insurancepremium financing$916K Taxes from withheldshares$902K Net cash provided by(used in) operating...-$15,970K Canceled cashflow$55,164K Net loss-$59,002K Accounts payable-$3,796K Operating leaseliabilities-$3,207K Accrued liabilities-$2,413K Accounts receivable$2,090K Other non-currentassets$503K Amortization (accretion) ofpremium (discount) on...$123K

TREACE MEDICAL CONCEPTS, INC. (TMCI)

TREACE MEDICAL CONCEPTS, INC. (TMCI)